Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial

Feb.07.2024
Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial
Philippine newspaper Manila Standard calls for a reassessment of the country's e-cigarette law in an editorial.

The large Philippine newspaper Manila Standard recently published an editorial calling for a reassessment of the country's e-cigarette bill.


On July 25, 2022, the Republic Act No. 11900 was enacted in the Philippines with the aim of regulating the importation, sale, packaging, distribution, use, and promotion of "vaporized nicotine and non-nicotine products, as well as new tobacco products such as vape and heated tobacco products." However, in the past two years since its introduction, the law has lowered the age restriction for such products from 21 to 18 years old, lifted the ban on smoking and using heated tobacco products in public places, and allowed advertising and promotion of these products.


The law allows for the online sale of products with nicotine concentrations not exceeding 65 milligrams per milliliter (6.5%), and lowers the legal purchasing age from 21 to 18. This means that more young people will be able to use e-cigarettes as an alternative to smoking (the legal age to purchase cigarettes is 18).


The editorial argues that this law overlooks the fact that tobacco is the highest risk factor for causing deaths and disabilities in both smokers and non-smokers in 2019.


It is estimated that tobacco use was responsible for over 112,112 deaths, accounting for 27% of the total deaths in the Philippines that year.


According to researchers, 96,000 deaths (85%) are caused by smoking, while 22,000 deaths (19%) are caused by secondhand smoke. It is estimated that approximately 8 million people die prematurely every year due to cigarette smoke, which is a complex mixture of chemicals combined with aerosol particles or present in the gas phase. This has been a major health issue for several decades.


The report also noted that the main reasons why students use e-cigarettes include easy online access (32%), flavors (22%), and a perception that e-cigarettes are safer than traditional cigarettes (17%).


Editorial: The editorial asserts that e-cigarettes have not been around for a long time, and authorities are still uncertain about the long-term risks associated with their use. While the harm posed by vaping is considerably lesser than smoking, it cannot be deemed entirely harmless. This is where the problem lies. Therefore, the healthiest choice would be to abstain from smoking or vaping altogether.


The editorial also quotes health experts saying, "If someone uses e-cigarettes to quit smoking, their ultimate goal should be to eventually quit using e-cigarettes." The article further mentions that according to research, emerging data suggests a link between e-cigarettes and chronic lung diseases and asthma. Additionally, using both e-cigarettes and traditional cigarettes has also been associated with cardiovascular diseases.


In conclusion, there is not much difference between smoking and using e-cigarettes, as stated in the editorial. People generally believe that smoking is more harmful because the products are burned and smoke is inhaled into the lungs. However, research has shown that the damage caused by heating and inhaling solution vapor into the lungs is very similar to that of smoke. Based on this, the report calls for a reevaluation of the country's e-cigarette legislation.


The Manila Standard newspaper was established on February 11, 1987. It is controlled by the Romualdez political family, specifically the current Speaker of the House of Representatives, Ferdinand Martin Gomez Romualdez.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22